よむ、つかう、まなぶ。
10参考資料１ 新型コロナワクチンに関する資料 (78 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000192554_00027.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会（第52回 2／8）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
14
Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl
J Med 383, 2603-2615 (2020). https://doi.org:10.1056/NEJMoa2034577
15
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl
J Med 384, 403-416 (2021). https://doi.org:10.1056/NEJMoa2035389
16
Dunkle, L. M. et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States
and
N
Mexico.
Engl
J
Med
386,
531-543
(2022).
https://doi.org:10.1056/NEJMoa2116185
17
Falsey, A. R. et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl
J Med 385, 1627-1629 (2021). https://doi.org:10.1056/NEJMc2113468
18
Chu, L. et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an openlabel phase 2 trial. Nat Med 28, 1042-1049 (2022). https://doi.org:10.1038/s41591-02201739-w
19
Mallory, R. M. et al. Safety and immunogenicity following a homologous booster dose of
a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis
of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis 22, 1565-1576 (2022).
https://doi.org:10.1016/S1473-3099(22)00420-0
20
Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third
dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COVBOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398, 22582276 (2021). https://doi.org:10.1016/S0140-6736(21)02717-3
21
Hause, A. M. et al. Safety Monitoring of COVID-19 mRNA Vaccine Second Booster
Doses Among Adults Aged >/=50 Years - United States, March 29, 2022-July 10, 2022.
MMWR
Morb
Mortal
Wkly
Rep
71,
971-976
(2022).
https://doi.org:10.15585/mmwr.mm7130a4
22
Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
through
6
Months.
N
Engl
J
Med
385,
1761-1773
(2021).
https://doi.org:10.1056/NEJMoa2110345
23
Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months
in a large integrated health system in the USA: a retrospective cohort study. Lancet 398,
1407-1416 (2021). https://doi.org:10.1016/S0140-6736(21)02183-8
24
Fowlkes, A. L. et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA
Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and
Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR
Morb Mortal Wkly Rep 71, 422-428 (2022). https://doi.org:10.15585/mmwr.mm7111e1
25
El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of
Blinded
Phase.
N
Engl
J
78
Med
385,
1774-1785
(2021).
Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl
J Med 383, 2603-2615 (2020). https://doi.org:10.1056/NEJMoa2034577
15
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl
J Med 384, 403-416 (2021). https://doi.org:10.1056/NEJMoa2035389
16
Dunkle, L. M. et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States
and
N
Mexico.
Engl
J
Med
386,
531-543
(2022).
https://doi.org:10.1056/NEJMoa2116185
17
Falsey, A. R. et al. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl
J Med 385, 1627-1629 (2021). https://doi.org:10.1056/NEJMc2113468
18
Chu, L. et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an openlabel phase 2 trial. Nat Med 28, 1042-1049 (2022). https://doi.org:10.1038/s41591-02201739-w
19
Mallory, R. M. et al. Safety and immunogenicity following a homologous booster dose of
a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis
of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis 22, 1565-1576 (2022).
https://doi.org:10.1016/S1473-3099(22)00420-0
20
Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third
dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COVBOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398, 22582276 (2021). https://doi.org:10.1016/S0140-6736(21)02717-3
21
Hause, A. M. et al. Safety Monitoring of COVID-19 mRNA Vaccine Second Booster
Doses Among Adults Aged >/=50 Years - United States, March 29, 2022-July 10, 2022.
MMWR
Morb
Mortal
Wkly
Rep
71,
971-976
(2022).
https://doi.org:10.15585/mmwr.mm7130a4
22
Thomas, S. J. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
through
6
Months.
N
Engl
J
Med
385,
1761-1773
(2021).
https://doi.org:10.1056/NEJMoa2110345
23
Tartof, S. Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months
in a large integrated health system in the USA: a retrospective cohort study. Lancet 398,
1407-1416 (2021). https://doi.org:10.1016/S0140-6736(21)02183-8
24
Fowlkes, A. L. et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA
Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and
Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022. MMWR
Morb Mortal Wkly Rep 71, 422-428 (2022). https://doi.org:10.15585/mmwr.mm7111e1
25
El Sahly, H. M. et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of
Blinded
Phase.
N
Engl
J
78
Med
385,
1774-1785
(2021).